In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK, Allergan cross license Botox, Imitrex, and Amerge

Executive Summary

GlaxoSmithKline PLC and Allergan have entered into a cross-licensing agreement that gives GSK development and marketing rights in Japan and China to Allergan's neuromodulator Botox (botulinum toxin type A), and Allergan US co-promotion rights for five years to GSK's migraine drugs Amerge (naratriptan) tablets and Imitrex Statdose System (sumatriptan succinate) for injection.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies